Ionis director’s spouse entity buys 20,000 shares

IONIS PHARMACEUTICALS INC director Michael R. Hayden reported two open-market purchases of common stock by Genworks 2 Consulting, Inc., an entity through which his spouse holds shares with sole voting and investment power.

Rhea-AI Filing Summary

IONIS PHARMACEUTICALS INC director Michael R. Hayden reported two open-market purchases of common stock by Genworks 2 Consulting, Inc., an entity through which his spouse holds shares with sole voting and investment power. Genworks 2 acquired 15,000 shares on July 30, 2026 at a weighted-average price of $53.38 and 5,000 shares on July 31, 2026 at a weighted-average price of $51.60, for a total of 20,000 additional indirectly held shares. Hayden also reports direct ownership of 54,298 Ionis common shares.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 3 txns

Insider Hayden Michael R

Role Director

Bought 20,000 shs ($1.06M)

Type	Security	Shares	Price	Value
Purchase	Common Stock F3, F2	5,000	$51.60	$258K
Purchase	Common Stock F1, F2	15,000	$53.38	$801K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 24,000 shares (Indirect, by Spouse); Common Stock — 54,298 shares (Direct)

Footnotes (3)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $53.00 to $53.58 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4.
2. F2. These securities are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2.
3. F3. The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $51.45 to $51.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) on this Form 4.

Key Figures

Shares purchased 2026-07-30: 15000 shares Shares purchased 2026-07-31: 5000 shares Weighted-average price 2026-07-30: $53.38 per share +2 more

5 metrics

Shares purchased 2026-07-30 15000 shares Indirect open-market purchase by Genworks 2 at weighted-average $53.38

Shares purchased 2026-07-31 5000 shares Indirect open-market purchase by Genworks 2 at weighted-average $51.60

Weighted-average price 2026-07-30 $53.38 per share Multiple trades with prices from $53.00 to $53.58 inclusive

Weighted-average price 2026-07-31 $51.60 per share Multiple trades with prices from $51.45 to $51.70 inclusive

Direct holdings after transactions 54298 shares Directly owned Ionis common stock as of July 30, 2026 holding entry

Key Terms

weighted average price, sole voting and investment power, indirect ownership, open market or private transaction

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

sole voting and investment power financial

"The Reporting Person's spouse has sole voting and investment power"

indirect ownership financial

"These securities are held by Genworks 2 Consulting, Inc."

open market or private transaction financial

"Purchase in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock purchases did Ionis Pharmaceuticals (IONS) disclose in this Form 4?

Ionis Pharmaceuticals reported that an entity associated with director Michael R. Hayden’s spouse bought 20,000 common shares in total, split between 15,000 shares on July 30, 2026 and 5,000 shares on July 31, 2026 in open-market transactions.

At what prices were the Ionis (IONS) shares purchased by the family entity?

The family entity purchased 15,000 shares at a weighted-average price of $53.38 on July 30, 2026 and 5,000 shares at a weighted-average price of $51.60 on July 31, 2026, each based on multiple trades within narrow price ranges.

Who actually holds voting and investment power over the Ionis (IONS) shares bought in this filing?

The purchased Ionis shares are held by Genworks 2 Consulting, Inc., and the footnotes state that Michael R. Hayden’s spouse has sole voting and investment power over these indirectly reported shares, rather than Hayden personally exercising that authority.

How many Ionis (IONS) shares does Michael R. Hayden report owning directly after these transactions?

Separate from the indirect family holdings, Michael R. Hayden reports 54,298 Ionis common shares held directly as of July 30, 2026, according to the holding entry included alongside the reported open-market purchase transactions.

Were the Ionis (IONS) insider purchases made in a single trade or multiple trades?

Both reported purchases were executed as multiple trades. Footnotes explain that the prices shown are weighted averages, with individual trade prices ranging from $53.00 to $53.58 and from $51.45 to $51.70 for the respective transaction dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:43 PM Accepted by SEC EDGAR 07/31/2026 - 04:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hayden Michael R

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2026		P		15,000	A	$53.38(1)	19,000	I	by Spouse(2)
Common Stock	07/31/2026		P		5,000	A	$51.6(3)	24,000	I	by Spouse(2)
Common Stock								54,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $53.00 to $53.58 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4.

2. These securities are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2.

3. The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $51.45 to $51.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: Michael R. Hayden	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)